9. (Amended) The method according to claim 8, wherein said pharmaceutical composition is ~~administered by~~ subcutaneous, intradermal or intramuscular injection.

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(714)708-8555

LRS/lmt
0147-0229P

Attachment: Version with Markings to Show Changes Made

(Rev. 02/12/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

The claims have been amended as follows:

1. (Amended) [Use of an antibody which is directed against the cellular membrane antigen EP-CAM for the preparation of a] A pharmaceutical composition for [the prophylactic and/or therapeutic] vaccination against cancer comprising at least one antibody directed against the cellular membrane antigen Ep-CAM.

2. (Amended) The [use] pharmaceutical composition of claim 1, wherein [the] said antibody is of animal origin.

3. (Amended) The [use] pharmaceutical composition of claim 1 [or 2], wherein [the] said antibody is a monoclonal antibody.

4. (Amended) The [use] pharmaceutical composition of claim 3, wherein [the] said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO:1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO:2.

5. (Amended) The [use] pharmaceutical composition of any one of claims 1-3, wherein [the] said antibody has the same fine specificity of binding as the antibody defined in claim 4.

6. (Amended) The [use of any one of claims 1 to 5] pharmaceutical composition of claim 1, wherein [two or more] said antibodies [which] are directed against different epitopes of the membrane antigen [are used in combination with each other].

7. (Amended) The [use of any one of claims 1 to 6, wherein the] pharmaceutical composition of claim 1, further comprising [comprises also] at least one vaccine adjuvant.

8. (Amended) [The use of any one of claims 1 to 7, wherein] A method of vaccination against cancer comprising administering to a patient in need thereof the pharmaceutical composition [is suitable for the administration of the antibody] of claim 1 at a dosage in the range of 0.01 to 4 mg antibody.

9. (Amended) The [use of any one of claims 1 to 9,] method according to claim 8, wherein [the] said pharmaceutical composition is [suitable for the administration] administered by subcutaneous, intradermal or intramuscular injection.